GNK301 / GeNeuro - LARVOL DELTA

Experimental ALS therapy targeting viral protein receives European patent (ALS News Today) - "Geneuro plans to begin Phase 1 clinical trials of GNK-301 in the U.S. and Europe during the second half of 2027...The European patent EP3570878B1...provides patent protection for GNK-301 and its uses for a specified period. Two related U.S. patents, numbers 10,723,787 and 10,981,977, have already been granted. These add to Geneuro’s portfolio of more than 25 issued and pending patents related to HERVs."

New P1 trial • Patent • Amyotrophic Lateral Sclerosis

New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro’s GNK-301 Presented at the 35th International Symposium on ALS/MND (Businesswire) - "GeNeuro...today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were presented at the 35th International Symposium on ALS/MND, taking place in Montreal, Canada, from December 6-8, 2024...The research...highlights the potential of GeNeuro’s GNK-301, a humanized monoclonal antibody targeting HERV-K ENV, a neurotoxic protein that is often found in the cerebrospinal fluid of ALS patients...Preclinical studies have shown that GNK-301 can be used to detect the presence of the HERV-K ENV protein in a laboratory test and that it can then be used as a medicine to neutralize the harmful effects of HERV-K ENV, protecting neurons and preventing damage to the blood-brain barrier."

Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders

GNK-301 a therapeutic antibody neutralizing HERV-K ENV for precision medicine in sporadic ALS (ALS-MND 2024) - "The results from the ongoing preclinical studies will be presented, including the mode of administration and biodistribution. Combining our therapeutic and diagnostic tools for clinical trials in sporadic ALS with principles of precision medicine is expected to allow identifying patients who could benefit from this targeted treatment and to avoid the now debated heterogeneity of ALS subtypes. However, this may also reinforce the need for using such diagnostic tests for an early detection and treatment in patients whose clinical deficits may not be reversible after a certain period and an extended loss of motoneurons."

SLC3A2 • SLC7A5 • TARDBP